4 Top Merrill Lynch Dividend-Paying Pharmaceutical Stocks to Buy Now
24/7 Wall St. screened the Merrill Lynch research universe for pharmaceutical stocks paying solid dividends that are rated Buy, and found four outstanding companies.
24/7 Wall St. screened the Merrill Lynch research universe for pharmaceutical stocks paying solid dividends that are rated Buy, and found four outstanding companies.
In a new research report Oppenheimer feels that the information technology services area is one the can be a late cycle outperformer for investors.
A new research report from Jefferies includes seven very solid reasons why the market should be going higher, and why a bear market is not likely now.
These four stocks are rated Buy at Merrill Lynch, and while they yield higher, they are not suitable for ultra-conservative income accounts.
24/7 Wall St. has screened the Merrill Lynch technology sector research universe for out-of-favor tech stocks that have solid potential for future growth.
High-yielding energy stocks make good sense for investors as it may take time for the sector to come back, and collecting large dividends while waiting makes the time go by quicker.
Aggressive traders looking for solid ideas with big upside from all over Wall Street will like a new research note from Stifel, which features four stocks to buy with huge potential.
Each week we cover the new value calls from the analysts at Jefferies, and increasingly, some of the calls may look surprising.
Cowen says the way to play biotech is with large cap sector leaders that can beat earnings estimates. It also thinks third-quarter earnings beats could highlight the risk of not owning biotech now.
A new research note from Stifel highlights three quality technology stocks that make good sense for the rest of this year and may offer aggressive growth investors very solid upside for 2016.
Four of Merrill Lynch's current top pick energy stocks also offer dividends that are in some cases outstanding.
A new research report from Jefferies focuses in on some growth stock calls that are decidedly more aggressive, but that also could have tremendous upside potential.
A new research note from Oppenheimer features companies that may continue to benefit from spending on what they dub the “rapid widespread rearchitecting to cloud services.”
While insider buying was steady last week, the typical earnings slowdown is in place as windows for insiders to buy and sell are closing.
Since the late August sell-off and through September, we saw very light insider selling, which actually was a very bullish sign for the markets.
In a new report, UBS thinks that third-quarter earnings reports for utility sector leaders could come in strong and that disappointments will be at a minimum.
These three top biotech names are very good bets for investors looking to add high-quality companies with less volatility and binary clinical data risk.
While these technology leaders are still more suitable for aggressive growth accounts, the sector leadership combined with the strong dividends make them good bets for patient long-term technology investors.
In a new report, Jefferies has a plethora of new value calls, and these four top stocks could be solid winners.
Oppenheimer has initiated coverage on two companies and upgrades another that could all thrive in the clean-tech arena.